{"id":68662,"date":"2026-06-22T19:49:36","date_gmt":"2026-06-22T11:49:36","guid":{"rendered":"https:\/\/flcube.com\/?p=68662"},"modified":"2026-06-22T19:49:38","modified_gmt":"2026-06-22T11:49:38","slug":"mercks-capvaxive-pneumococcal-vaccine-expands-to-pediatric-population-with-fda-approval-for-ages-2-17","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68662","title":{"rendered":"Merck&#8217;s Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Merck &amp; Co., Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>), known as MSD outside the United States, announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved an expanded indication for <strong>Capvaxive<\/strong> (21-valent pneumococcal conjugate vaccine) to include <strong>children and adolescents aged 2 to 17 years<\/strong>. The single-dose vaccine, originally designed to address pneumococcal serotypes causing invasive disease in adults, now extends protection to a critical pediatric population.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Regulatory Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Indication expansion<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Capvaxive (21-valent pneumococcal conjugate vaccine)<\/td><\/tr><tr><td><strong>New Age Group<\/strong><\/td><td>Children and adolescents aged 2\u201317 years<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Single dose<\/td><\/tr><tr><td><strong>Original Target<\/strong><\/td><td>Adult invasive pneumococcal disease (IPD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-differentiation-amp-serotype-coverage\" class=\"wp-block-heading\">Product Differentiation &amp; Serotype Coverage<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unique Serotype Profile:<\/strong> Capvaxive includes <strong>eight serotypes not covered<\/strong> by other approved pneumococcal vaccines: <strong>15A, 15C, 16F, 23A, 23B, 24F, 31, and 35B<\/strong><\/li>\n\n\n\n<li><strong>Total Coverage:<\/strong> 21 serotypes targeting the most prevalent causes of invasive pneumococcal disease<\/li>\n\n\n\n<li><strong>Pediatric Relevance:<\/strong> Several unique serotypes (particularly 15A, 23B, and 35B) have emerged as significant causes of pediatric IPD in recent epidemiological studies<\/li>\n\n\n\n<li><strong>Single-Dose Convenience:<\/strong> Simplified administration compared to multi-dose pediatric pneumococcal vaccine schedules<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-market-impact\" class=\"wp-block-heading\">Strategic Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pediatric Vaccination Gap:<\/strong> Current pediatric pneumococcal vaccines cover 13\u201315 serotypes, leaving children vulnerable to emerging serotypes responsible for up to <strong>25% of pediatric IPD cases<\/strong><\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Capvaxive directly competes with Pfizer&#8217;s Prevnar 20 and Merck&#8217;s own Vaxneuvance (15-valent), but offers the <strong>broadest serotype coverage<\/strong> in the pediatric market<\/li>\n\n\n\n<li><strong>Revenue Expansion:<\/strong> The pediatric indication could add <strong>$300\u2013500 million annually<\/strong> to Capvaxive&#8217;s peak sales potential, building on its established adult market presence<\/li>\n\n\n\n<li><strong>Public Health Impact:<\/strong> Enhanced serotype coverage addresses evolving pneumococcal epidemiology, where non-vaccine serotypes have increased in prevalence following widespread vaccination<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-strategy-amp-implementation\" class=\"wp-block-heading\">Commercial Strategy &amp; Implementation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Merck plans to leverage its existing pediatric vaccine distribution infrastructure and relationships with pediatric healthcare providers to rapidly integrate Capvaxive into routine immunization schedules. The company is also engaging with the <strong>Advisory Committee on Immunization Practices (ACIP)<\/strong> to secure formal recommendations for the expanded age group, which would facilitate insurance coverage and public health program adoption.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The approval positions Merck to capture market share from both existing pediatric pneumococcal vaccines and off-label use of adult formulations, while addressing unmet medical needs in serotype coverage.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to competitive dynamics, reimbursement decisions, and public health policy developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (MSD, NYSE: MRK), known as MSD outside the United States, announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68663,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[2675,176,903,68,15],"class_list":["post-68662","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-pediatric-drugs","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck&#039;s Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK), known as MSD outside the United States, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Capvaxive (21-valent pneumococcal conjugate vaccine) to include children and adolescents aged 2 to 17 years. The single-dose vaccine, originally designed to address pneumococcal serotypes causing invasive disease in adults, now extends protection to a critical pediatric population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68662\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck&#039;s Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (MSD, NYSE: MRK), known as MSD outside the United States, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Capvaxive (21-valent pneumococcal conjugate vaccine) to include children and adolescents aged 2 to 17 years. The single-dose vaccine, originally designed to address pneumococcal serotypes causing invasive disease in adults, now extends protection to a critical pediatric population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68662\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T11:49:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T11:49:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2201-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck&#8217;s Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17\",\"datePublished\":\"2026-06-22T11:49:36+00:00\",\"dateModified\":\"2026-06-22T11:49:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662\"},\"wordCount\":404,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2201-1.webp\",\"keywords\":[\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"Pediatric drugs\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68662#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68662\",\"name\":\"Merck's Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2201-1.webp\",\"datePublished\":\"2026-06-22T11:49:36+00:00\",\"dateModified\":\"2026-06-22T11:49:38+00:00\",\"description\":\"Merck & Co., Inc. (MSD, NYSE: MRK), known as MSD outside the United States, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Capvaxive (21-valent pneumococcal conjugate vaccine) to include children and adolescents aged 2 to 17 years. The single-dose vaccine, originally designed to address pneumococcal serotypes causing invasive disease in adults, now extends protection to a critical pediatric population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68662\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2201-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2201-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck's Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68662#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck&#8217;s Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck's Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17 - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co., Inc. (MSD, NYSE: MRK), known as MSD outside the United States, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Capvaxive (21-valent pneumococcal conjugate vaccine) to include children and adolescents aged 2 to 17 years. The single-dose vaccine, originally designed to address pneumococcal serotypes causing invasive disease in adults, now extends protection to a critical pediatric population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68662","og_locale":"en_US","og_type":"article","og_title":"Merck's Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17","og_description":"Merck & Co., Inc. (MSD, NYSE: MRK), known as MSD outside the United States, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Capvaxive (21-valent pneumococcal conjugate vaccine) to include children and adolescents aged 2 to 17 years. The single-dose vaccine, originally designed to address pneumococcal serotypes causing invasive disease in adults, now extends protection to a critical pediatric population.","og_url":"https:\/\/flcube.com\/?p=68662","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-22T11:49:36+00:00","article_modified_time":"2026-06-22T11:49:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2201-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68662#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68662"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck&#8217;s Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17","datePublished":"2026-06-22T11:49:36+00:00","dateModified":"2026-06-22T11:49:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68662"},"wordCount":404,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68662#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2201-1.webp","keywords":["Merck Sharp &amp; Dohme","MSD","NYSE: MRK","Pediatric drugs","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68662#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68662","url":"https:\/\/flcube.com\/?p=68662","name":"Merck's Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68662#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68662#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2201-1.webp","datePublished":"2026-06-22T11:49:36+00:00","dateModified":"2026-06-22T11:49:38+00:00","description":"Merck & Co., Inc. (MSD, NYSE: MRK), known as MSD outside the United States, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Capvaxive (21-valent pneumococcal conjugate vaccine) to include children and adolescents aged 2 to 17 years. The single-dose vaccine, originally designed to address pneumococcal serotypes causing invasive disease in adults, now extends protection to a critical pediatric population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68662#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68662"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68662#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2201-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2201-1.webp","width":1080,"height":608,"caption":"Merck's Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68662#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck&#8217;s Capvaxive Pneumococcal Vaccine Expands to Pediatric Population with FDA Approval for Ages 2-17"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2201-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68662"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68662\/revisions"}],"predecessor-version":[{"id":68664,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68662\/revisions\/68664"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68663"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68662"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68662"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}